PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics (PTCT) reported $164.68 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 22.8%. EPS of -$1.67 for the same period compares to -$0.24 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $304.72 million, representing a surprise of -45.96%. The company delivered an EPS surprise of -700.58%, with the consensus EPS estimate being -$0.21.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Net product revenue: $183.99 million versus the four-analyst average estimate of $174.53 million. The reported number represents a year-over-year change of +18.9%.Revenues- Royalty revenue: $79.39 million compared to the $70.77 million average estimate based on four analysts. The reported number represents a change of +36.5% year over year.Revenues- Net product revenue- Translarna: $39 million compared to the $40.42 million average estimate based on three analysts. The reported number represents a change of -58.4% year over year.Revenues- Net product revenue- Emflaza: $27.1 million versus $29.58 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -46.3% change.Revenues- Collaboration and license revenue: $-0.07 million versus $118.82 million estimated by two analysts on average.View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have returned -8.8% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks